Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658548 | 0.93 | MDM2 (0.72) | MDM2TP53 | |
| SCHEMBL658907 | 0.92 | MDM2 (0.80) | MDM2TP53 | |
| SCHEMBL658273 | 0.88 | MDM2 (0.89) | MDM2TP53 | |
| SCHEMBL659272 | 0.87 | MDM2 (0.78) | MDM2TP53 | |
| SCHEMBL660289 | 0.87 | MDM2 (0.78) | MDM2TP53 | |
| SCHEMBL657605 | 0.85 | MDM2 (0.81) | MDM2TP53 | |
| SCHEMBL661503 | 0.85 | MDM2 (0.90) | MDM2TP53 | |
| SCHEMBL223067 | 0.85 | MDM2 (0.85) | MDM2TP53 | |
| SCHEMBL223066 | 0.85 | MDM2 (0.85) | MDM2TP53 | |
| SCHEMBL660392 | 0.84 | MDM2 (0.79) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | claimed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | claimed |
| WO-2012022707-A1 | SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | BARTKOVITZ DAVID JOSEPH (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046306-A1 | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists | MDM2, TP53, RB1 | MDM2 1/4885TP53 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.